MedTrace Logo

Candesartan Effect in Second Stage Arterial Hypertension

NCT00621153 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 214

Last updated 2010-03-23

Study results available
· View outcomes & findings →

Summary

To compare the changes in mean sitting DBP from baseline after 4 weeks of therapy with either candesartan cilexetil/HCT combination therapy or candesartan cilexetil monotherapy regimen

Conditions

  • Stage II Hypertension

Interventions

DRUG

Candesartan Cilexetil

Candesartan Cilexetil 16 mg oral

DRUG

Hydrochlorothiazide

Hydrochlorothiazide 12.5 mg

DRUG

Candesartan Cilexetil

Candesartan Cilexetil 32 mg oral

Sponsors & Collaborators

Principal Investigators

  • Dong Hoon Choi · Severance Hospital

  • Joonwoo Bahn · AstraZeneca Korea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00621153 on ClinicalTrials.gov